Bye-bye cool tickers? DNA and BUD head for bin

August 11, 2008


Pity the guys who dreamt up two of Wall Street’s coolest tickers — DNA and BUD — both of which look set to be consigned to the dustbin of history.

Genentech grabbed the three letters synonymous with biotechnology by being in on the ground floor of the gene revolution. Anheuser-Busch was lucky enough to have a beer brand known everywhere by one syllable. Now both look doomed. dna-global-logo.gif

Genentech faces a $43.7 billion bid from Roche for the 44 percent of the Californian biotech group that it doesn’t already own. Genentech is expected to succomb, albeit after a possibly sweetened offer. Anheuser has already agreed to a $52 billion takeover by InBev.

Their demise may take some of the fun out of stock trading – but investors shouldn’t despair. The thoughtful punter still has other options. sothebys.jpg

For example:

BID for auctioneer Sotheby’s

HOG for Harley-Davidson

TAP for brewer Molson Coors

JAVA for Sun Microsystems

CAR for Avis Budget

PZZA for pizza company Papa John’s

BLUD for blood test group Immucor

LUV for Southwest Airlines (after its Love Field airport in Dallas)

LVB for Steinway Musical Instruments (after Ludwig van Beethoven)

LIZ for Liz Claiborne

harley-davidson.jpgPUB for Britain’s Punch Taverns

WOOF for pet healthcare provider VCA Antech…does that take the biscuit?

And not forgetting the grandaddy of them all:

T for AT&T (it stands for telephone, of course).

Genentech, meanwhile, will at least keep one thing when it becomes part of a Roche — an ultra-cool address at 1 DNA Way, South San Francisco.

(Photos: Reuters)

One comment so far | RSS Comments RSS

V for visa is one that comes to mind. It has stood for victory in the past, as well as peace.. but in this case it will be vendetta when people see their credit card bills! but seriously BUD was subpar beer abd should go oob.


Post Your Comment

We welcome comments that advance the story through relevant opinion, anecdotes, links and data. If you see a comment that you believe is irrelevant or inappropriate, you can flag it to our editors by using the report abuse links. Views expressed in the comments do not represent those of Reuters. For more information on our comment policy, see